The weekly litigation news digest is live. Subscribe now

IP Verse

Controlled Release Formulations Of Levodopa And Uses Thereof - EP2234963

The patent EP2234963 was granted to Impax Laboratories on Apr 8, 2020. The application was filed on Dec 26, 2008 under application number EP08866933A. The patent is currently recorded with a legal status of "Revoked".

EP2234963

IMPAX LABORATORIES
Application Number
EP08866933A
Filing Date
Dec 26, 2008
Status
Revoked
Jan 24, 2025
Publication Date
Apr 8, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
LUIGIJan 7, 2021TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSJan 7, 2021D YOUNGADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007148238
INTERNATIONAL-SEARCH-REPORTUS2005203185
INTERNATIONAL-SEARCH-REPORTUS2006013875
INTERNATIONAL-SEARCH-REPORTUS2007148238
OPPOSITIONEP1262198
OPPOSITIONEP1964566
OPPOSITIONUS2006013875
OPPOSITIONUS2007003621
OPPOSITIONUS2007148238
OPPOSITIONUS2007275060
OPPOSITIONWO2009085306
SEARCHEP1262198

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents